<DOC>
	<DOCNO>NCT01006252</DOCNO>
	<brief_summary>The primary purpose study see tasisulam affect metastatic melanoma compare paclitaxel measure overall survival .</brief_summary>
	<brief_title>A Study Tasisulam Versus Paclitaxel Treatment Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Have histologic and/or cytologic diagnosis metastatic melanoma ( Stage IV ) Have presence evaluable disease define Response Evaluation Criteria Solid Tumors ( RECIST 1.0 ) Have performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Scale Have progress 1 previous systemic treatment contain dacarbazine temozolomide metastatic melanoma Have discontinue previous therapy cancer , include chemotherapy , radiotherapy , immunotherapy , investigational therapy least 30 day ( 6 week mitomycinC nitrosoureas ) study enrollment recover acute effect therapy ( except alopecia ) Have serum albumin level great equal 3.0 g/dL great equal 30 g/L Have receive great equal 2 previous chemotherapycontaining systemic treatment regimens metastatic melanoma . An immunotherapy antibodybased regimen [ include biologic agent vaccinationbased treatment ] , treatment target agent ( e.g BRAF cKit inhibitor , count prior treatment regimen determine study eligibility , unless either combined cytotoxic drug ) . Have active central nervous system ( CNS ) leptomeningeal metastasis ( brain metastasis ) time study entry . Patients sign symptom neurological compromise appropriate radiographic imaging perform study entry rule occult brain metastasis . Patients history solitary CNS metastasis previously treat curative intent ( e.g. , stereotactic radiation surgery ) require steroid eligible . Are receive warfarin Have primary ocular mucosal melanoma Any previous treatment paclitaxel paclitaxelcontaining regimen metastatic melanoma Have serious concomitant disorder , include active bacterial , fungal , viral infection , incompatible study ( discretion investigator ) Have previously complete withdrawn study study investigate tasisulam Have know hypersensitivity paclitaxel Cremophor EL ( polyoxyethylated castor oil ) Are pregnant lactate Have receive recent ( within 30 day enrollment ) receive concurrent yellow fever vaccination Have know positive test result human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBSAg ) , hepatitis C antibody ( HCAb ) Are unable withhold dose nonsteroidal antiinflammatory drug ( NSAIDs ) protonpump inhibitor ( PPIs ) least 72 hour treatment tasisulam .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>metastatic</keyword>
	<keyword>second-line</keyword>
</DOC>